Xitra Therapeutics

Executive Summary

Xitra Therapeutics is a German biotechnology company founded in 2018 that focuses on developing small molecule therapeutics targeting the Mas and MrgD receptors within the renin-angiotensin system. By mimicking angiotensin-(1-7), the company aims to achieve improved oral bioavailability and potency. Its mission is to address life-threatening pediatric diseases, including congenital muscular dystrophy and epidermolysis bullosa. Xitra is privately held with limited public information, indicating an early-stage profile.

Upcoming Catalysts (preview)

• Q2 2026Preclinical Proof-of-Concept Data Release40% success
• TBDSeries A Financing Round50% success
• TBDRegulatory Filing or Partnership for Lead Program30% success